4D Molecular Therapeutics Receives Moderate Buy Rating from Analysts

Biotechnology company's stock given consensus recommendation by research firms

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average recommendation of "Moderate Buy" by the ten research firms covering the stock, according to MarketBeat.com. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, and eight have issued a buy recommendation on the company.

Why it matters

4D Molecular Therapeutics is a clinical-stage biotechnology company focused on developing targeted gene therapies for rare diseases. The Moderate Buy rating from analysts suggests they see potential in the company's pipeline and technology, which could signal positive momentum for the stock.

The details

The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $33.25. Several research firms have weighed in on FDMT, with Weiss Ratings reaffirming a "sell (d-)" rating, Chardan Capital restating a "buy" rating and $26.00 target price, and Barclays initiating coverage with an "overweight" rating and $33.00 price target.

  • 4D Molecular Therapeutics stock opened at $9.66 on Monday.

The players

4D Molecular Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing targeted gene therapies for rare diseases, founded in 2015 and headquartered in Emeryville, California.

Weiss Ratings

A research firm that reaffirmed a "sell (d-)" rating on 4D Molecular Therapeutics' stock.

Chardan Capital

A research firm that restated a "buy" rating and $26.00 target price on 4D Molecular Therapeutics' stock.

Barclays

A research firm that initiated coverage on 4D Molecular Therapeutics with an "overweight" rating and $33.00 price target.

Got photos? Submit your photos here. ›

The takeaway

The Moderate Buy rating from analysts on 4D Molecular Therapeutics' stock suggests the company's targeted gene therapy pipeline and technology platform are seen as having potential, despite one firm issuing a sell recommendation. Investors will likely watch for updates on the company's clinical programs and any further analyst commentary on the stock.